Clinical Trial Search

Primary: Kaplan Meier Estimate for Time to Disease Progression — 214.0 days

Primary: Response Rate (Clinical Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃…

Primary: Overall Survival (OS) Among All Randomized Patients — 9.3; 9.2 months — p=0.7583

Primary: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours…

Primary: Change in the Number of Wet Nights Between Baseline and Treatment Period II — 3.264; 1.451 wet nights — p=0.009

Primary: Number of Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Viral Load <50 Copies/mL — 108; 108; 59; 62 participants

Primary: Change in Contrast to Noise Ratio (CNR) Between Pre- and Post-contrast Magnetic Resonance Imaging (MRI) Scan of Central Nervous System (CNS) Lesions — 50.41; 43.47…

Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL)-C — -26.81; -11.81 percent change from baseline — p=<0.001

Primary: Percentage of Applicator Users Who Were Very Satisfied and Satisfied- User Satisfaction Questionnaire for Domain: Design & Technical Aspects — 99.1 Percentage of…

Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074

Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), 24 Months/Endpoint, ITT Population. — 1.22; 5.75 Percent Change — p=<0.0001

Primary: Subjects Experiencing Serious Adverse Events — 176; 98 participants — p=<0.05

Primary: Number of Participants Who Achieved Clinical Resolution at Visit 3 — 127; 123 Participants

Primary: Mean Neuropathic Pain Score at Visit 3 (Week 1) — 51.00; 50.70 Units on a Scale

Primary: Participants Who Achieved Clinical Resolution — 82; 74 Participants